Penn Mental Health AIDS Research Center Core E: Laboratory Biomarkers, Quantitative Pharmacology, Neuroimaging, and Neurobehavioral Characterization Core.

Slides:

Advertisements

Similar presentations

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Advertisements

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Penn Mental Health AIDS Research Center (PMHARC) Developmental Awards Program Pre-application Meeting January 29, 2015.

Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.

Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,

Human studies of neurokinin-1 receptor antagonists in HIV-1

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Lecture outline The nomenclature of Immunology Types of immunity (innate and adaptive; active and passive; humoral and cell- mediated) Features of immune.

Metabonomics A New Potential Diagnostic Tool David Huffman Western Michigan University WDA 2010.

Bioscience/Biomedical Research at Idaho State University Christopher Daniels, Ph.D. Director, ISU Biomedical Research Institute and Professor of Pharmaceutical.

Biomarkers and Risk Assessment for Chromium(VI) Qingshan Qu, MD (PI) Roy Shore, PhD (Co-I) Dept. of Environmental Med. NYU School of Medicine.

An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec

What Do Toxicologists Do?

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

CELL MEMBRANE MICROPARTICLES IN BLOOD AND BLOOD PRODUCTS: POTENTIALLY PATHOGENIC AGENTS AND BIOMARKERS JAN SIMAK, Ph.D. Laboratory of Cellular Hematology,

Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,

CLL Research Consortium FISH studies, Core C June, 2005 NCI Submission.

LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

DNA methylation as an epigenetic marker in HIV-2 disease in West Africa? Alberta Davis MRC Laboratories, Gambia 18th January 2013.

Simoa Accelerator Laboratory

Supercourse Environmental Exposure Assessment And Biomarkers Wael Al-Delaimy, MD, PhD.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

BIOMARKER STUDIES IN CLINICAL TRIALS Vicki Seyfert-Margolis, PhD.

DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.

Clinical Pharmacy Part 2

PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.

Jeffrey S. Barrett, PhD, FCP, Dimple Patel, MS, Bhuvana Jayaraman, BS, Mahesh Narayan, MS, Athena Zuppa, MD, FCP Laboratory for Applied PK/PD, Division.

Detecting Infectious HIV in Human Milk Miles W. Cloyd, Ph.D. Professor Department of Microbiology & Immunology University of Texas Medical Branch Galveston,

Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.

Penn Mental Health AIDS Research Center Core F: Biostatistics and Data Management Core November 19 th, 2014 Core Director: Warren B. Bilker, Ph.D. Co-Director:

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

Nos Commanditaires : IRIC 16 avril, h00 Salle S1-151 Pavillon Jean-Coutu Université de Montréal.

Biomarkers: types ? Genome DNA Epigenome Genomic Biomarkers

Biologic Monitoring A. H. Mehrparvar, MD Occupational Medicine department Yazd University of Medical Sciences.

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

Welcome Advanced Clinical Chemistry BISC Dr Atef Masad PhD Biomedicine Uinited Kingdom Advanced Clinical Chemistry BISC 6360.

Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.

Foundation Knowledge and Skills

Cytotoxic T Lymphocyte Assays

University of Pavia Dep. of Electrical, Computer and Biomedical Engineering Laboratory of Bioinformatics, Mathematical Modelling and Synthetic Biology.

SuPAR and sICAM-1 as Immune Markers for Treatment Response in Ethiopian TB patients with and without HIV co-infection Wegene T. Mekasha ICASA, Addis Ababa.

Myotonic Dystrophy Research: What’s Next

M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B

Biomedical Data Science for Precision Medicine

Biomedical Data Science for Precision Medicine

Suppl Figure 1 NSCLC OvCa A B

PANEL 1 All events Lymphocytes (FSC-A v SSC-A)

Penn Mental Health AIDS Research Center

Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.

UCSF Core Facilities Enterprise

Improved Vitamin D3 status is associated with increases in circulating T-regulatory cells during pregnancy Jennifer K. Mulligan, PhD Dept of Otolaryngology,

From Bench to Clinical Applications: Money Talks

Simone M. Shurland, Ph.D., Division of Anti-Infective Products

Volume 25, Issue 1, Pages (January 2017)

Biomedical Data Science for Precision Medicine

FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection by Timothy J. Wilson, Rachel M. Presti,

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

O. Turriziani, M. Andreoni, G. Antonelli

Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut Leticia Tordesillas, PhD, Adeeb H. Rahman,

My typical day as a scientist in pre-clinical at AZ/MedI

Immunophenotyping of lymphocyte subsets.

Benjamin T. Prince, MD, Msci, Ashley L. Devonshire, MD, MPH, Kristin A

Adaptive (specific ) Immunity

Expansion of cytolytic CD4+CD28− T cells in end-stage renal disease

Volume 15, Issue 3, Pages (March 2014)

Unit 8: Forensic Serology

Presentation transcript:

Penn Mental Health AIDS Research Center Core E: Laboratory Biomarkers, Quantitative Pharmacology, Neuroimaging, and Neurobehavioral Characterization Core January 29 th, 2015 Core Director: Steven D. Douglas, M.D. Co-Director: Ruben C. Gur, Ph.D. Co-Director: Athena Zuppa, M.D., M.S.C.E.

Core E: Specific Aims Laboratory Biomarkers Aim 1 The Core Immunology-Virology Laboratory performs assays of body fluids including plasma and CSF markers related to AIDS and leukocyte markers related to HIV/AIDS, psychiatric disease, and co-morbidities. Aim 2 The Core maintains a specimen repository, which includes plasma, serum, cells, and DNA.

Core E: Specific Aims (continued) Quantitative Pharmacology Aim 3 The Quantitative Pharmacology Laboratory utilizes and develops bioanalytical methodology to detect drug and biomarker exposure in various biologic media. Biological assays are performed on cells, plasma, serum, urine, and CSF The Core provides metabolomic and metabonomic support to identify potential novel biomarkers of drug activity, subject characteristics which correlate with responsiveness to therapy and time-dependent markers of disease progression The Core performs In Silico and ADME screens in order to examine the interaction between psychotropic drugs and anti-viral drugs The Core provides pharmacokinetics, pharmacodynamics, and pharmacometric (PK/PD and PM) support to facilitate drug selection, target dosing, and dosing recommendations in all relevant Pilot Projects and interacts with the other Cores.

Core E: Specific Aims (continued) Neuroimaging and Neurobehavioral Characterization Aim 4 The Center for Neuroimaging in Psychiatry and the Brain Behavior Laboratory performs state of the art assessment of regional brain function in normative and clinical populations.

Core E: Services Labs by System Immune/InflammImmuneInflammStressCoagNeurodamageCardioGeneral FractalkineMIP-1αIFNγhsCRPCortisolD-dimerNFHFractalkineCBC IFN-γsCD14CD4/CD8LPS NFLsICAMGlucose IL-1βsCD163 Neopterin sVCAMβ-hCG IL-6sICAM sCD163 Viral load IL-8sVCAM Genomic DNA IL-10TNFα MCP-1TNFα-R1 Monocyte and NK flow cytometry panels are available, as appropriate, for Pilot Projects.

Core E: Services Labs by Comorbidities CardiacRenal/LiverPsychiatric Creatine KinaseCreatinineCortisol Na IL-6 KKTNFα ASTClhsCRP HDLCaIFN-γ LDLBUNCD4/CD8 TriglyceridesTotal bilirubin CholesterolDirect bilirubin GlucoseTotal protein ALP AST ALT CO2 Albumin

Core E: Services Peripheral Blood Leukocyte Cell Phenotypes T cell phenotypes: Naïve T cells: CD3+ CD4+ or CD8+ CCR7+ CD45RO- CD62L+ CD95- Central memory T cells: CD3+ CD4+ or CD8+ CCR7+ CD45RO+ Effector memory T cells: CD3+ CD4+ or CD8+ CCR7- CD45RO+ Effector T cells: CD3+ CD4+ or CD8+ CCR7- CD45RO- Stem cell-like T cells: CD3+ CD4+ or CD8+ CCR7+ CD45RO- CD62L+ CD95+

Core E: Services Peripheral Blood Leukocyte Cell Phenotypes Monocyte and NK Cell phenotypes Classical monocytes: CD14 high CD16 low Intermediate monocytes: CD14 high CD16 positive Non-conventional monocytes: CD14 low CD16 high Typical NK cells, ~90% (mainly cytotoxic): CD56dim CD16 high NK cells precursor-like ~10% (more specialized on cytokine production): CD56 bright CD16 low